Boomfish Wealth Group LLC Grows Stock Holdings in Danaher Co. (NYSE:DHR)

Boomfish Wealth Group LLC increased its stake in Danaher Co. (NYSE:DHR) by 14.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,743 shares of the conglomerate’s stock after purchasing an additional 468 shares during the quarter. Boomfish Wealth Group LLC’s holdings in Danaher were worth $859,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in DHR. Decker Retirement Planning Inc. bought a new position in shares of Danaher in the fourth quarter worth $31,000. Teachers Insurance & Annuity Association of America purchased a new position in Danaher during the third quarter worth about $39,000. MidAtlantic Capital Management Inc. bought a new position in Danaher in the 3rd quarter worth about $40,000. FSA Wealth Management LLC purchased a new stake in shares of Danaher in the 3rd quarter valued at about $50,000. Finally, Darwin Wealth Management LLC bought a new stake in shares of Danaher during the 3rd quarter valued at about $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 0.3 %

NYSE:DHR opened at $223.16 on Friday. The stock has a market cap of $161.19 billion, a price-to-earnings ratio of 42.27, a PEG ratio of 4.22 and a beta of 0.83. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The company’s 50 day moving average price is $235.89 and its 200-day moving average price is $253.45. Danaher Co. has a 52 week low of $221.34 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.72% and a net margin of 16.33%. During the same quarter in the previous year, the firm earned $2.09 EPS. On average, equities research analysts forecast that Danaher Co. will post 8.15 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.48%. Danaher’s payout ratio is presently 20.45%.

Analysts Set New Price Targets

A number of research firms recently commented on DHR. TD Cowen increased their target price on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. KeyCorp raised their price objective on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $277.00 target price (down previously from $299.00) on shares of Danaher in a research note on Thursday. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a report on Thursday, October 31st. Finally, UBS Group reduced their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.